Last week, two of the biggest and oldest companies in the burgeoning AI drug discovery space announced a surprise merger. In a roughly 75-25 deal, Recursion Bio and Exscientia will (if the merger goes ...
In one of the biggest M&A deals involving artificial intelligence-focused drug developers to date, Recursion Pharma has agreed to join with Exscientia in an all-stock transaction valued at $688 ...
In early December 2025, Recursion Pharmaceuticals released clinical data from the TUPELO Phase 1b/2 trial of REC-4881, providing fresh insight into the candidate’s safety and efficacy profile. This ...
Elvis Picardo is a regular contributor to Investopedia and has 25+ years of experience as a portfolio manager with diverse capital markets experience. Samantha (Sam) Silberstein, CFP®, CSLP®, EA, is ...
Adam Hayes, Ph.D., CFA, is a financial writer with 15+ years Wall Street experience as a derivatives trader. Besides his extensive derivative trading expertise, Adam is an expert in economics and ...
Tuerk said the failed override vote leaves intact his original budget with a 4% tax increase. However, City Council's lawyer said the veto leaves the city in limbo with no budget for 2026. Tuerk said ...
Some were public leaders; others were stalwarts in business, education, medicine, religion and other areas. The year’s list also included a world-renowned broadcast journalist, a Morning Call ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback